Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

3(50.0%)

6Total

Phase 2(3)

Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07283835Phase 2Recruiting

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Role: lead

NCT07479485Phase 1Not Yet Recruiting

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

Role: lead

NCT07066657Phase 1Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

Role: collaborator

NCT07394244Phase 2Not Yet Recruiting

Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma

Role: collaborator

NCT07093970Phase 1Recruiting

A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors

Role: lead

NCT07354984Phase 2Not Yet Recruiting

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Role: collaborator

All 6 trials loaded